New Zealand markets closed
  • NZX 50

    10,813.92
    +135.25 (+1.27%)
     
  • NZD/USD

    0.6319
    +0.0038 (+0.60%)
     
  • NZD/EUR

    0.5979
    +0.0017 (+0.29%)
     
  • ALL ORDS

    6,762.40
    +71.00 (+1.06%)
     
  • ASX 200

    6,578.70
    +50.30 (+0.77%)
     
  • OIL

    107.06
    +2.79 (+2.68%)
     
  • GOLD

    1,828.10
    -1.70 (-0.09%)
     
  • NASDAQ

    12,105.85
    +408.17 (+3.49%)
     
  • FTSE

    7,208.81
    +188.36 (+2.68%)
     
  • Dow Jones

    31,500.68
    +823.32 (+2.68%)
     
  • DAX

    13,118.13
    +205.54 (+1.59%)
     
  • Hang Seng

    21,719.06
    +445.19 (+2.09%)
     
  • NIKKEI 225

    26,491.97
    +320.72 (+1.23%)
     
  • NZD/JPY

    85.3920
    +0.7130 (+0.84%)
     

Is This Growth Stock Defeated After Collapsing 22% in a Year?

·4-min read
Is This Growth Stock Defeated After Collapsing 22% in a Year?

With its shares down by more than 22% in the last 12 months, it's clear that Biogen (NASDAQ: BIIB) isn't the high-flying growth stock that it used to be. Since its failed attempt over the last year to get its fiercely criticized Alzheimer's disease drug Aduhelm approved for sale, the company's troubles have turned from bad to worse. Revenue and earnings from its core drug products are both down sharply over the last three years.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting